Treatment-Resistant Depression: Evidence-Based Management

Definition and Diagnostic Criteria

Treatment-resistant depression (TRD) is defined as failure to respond to at least two adequate trials of antidepressants with different mechanisms of action in the current depressive episode, as recommended by the American Psychiatric Association 1, 2
The minimum effective dosage for at least 4 weeks duration is required for an adequate trial, according to the National Institute of Mental Health 1, 2
Discontinuation due to side effects before completing 4 weeks should not be counted as a treatment failure for establishing TRD, as stated by the American Medical Association 1, 2
For prolonged current episodes, only treatment failures within the last 2 years should be considered, as suggested by the American Psychiatric Association 1

Confirm treatment history through careful documentation or use structured staging tools, such as the Maudsley Staging Method (MSM), which is the preferred staging instrument due to its prospective validation and superior predictive utility, as recommended by the National Institute of Mental Health 3, 4
The Maudsley Staging Method (MSM) uniquely incorporates disease characteristics, including duration of illness and baseline symptom severity, correctly predicting treatment resistance in >85% of cases, as reported by the American Psychiatric Association 5, 6

Verify TRD diagnosis by confirming failure of at least 2 adequate antidepressant trials with different mechanisms, as recommended by the American Medical Association 1, 2
Ensure each trial was at minimum effective dosage for ≥4 weeks, as stated by the National Institute of Mental Health 1, 2
Augmentation with atypical antipsychotics, such as aripiprazole, is the primary first-line strategy after inadequate response to at least one antidepressant at adequate dose for ≥4 weeks, as recommended by the American Psychiatric Association 1
Esketamine/ketamine is recommended for highly refractory cases, as reported by the National Institute of Mental Health 1, 2
Transcranial magnetic stimulation (TMS) should be considered for patients who have failed medication trials, as recommended by the American Medical Association 1, 2
Cognitive behavioral therapy should be used in conjunction with pharmacotherapy, as suggested by the American Psychiatric Association 2

All depression specifiers (melancholic, atypical, anxious, psychotic, mixed) should be considered within TRD, except bipolar depression, as stated by the American Psychiatric Association 2
Do not exclude patients from treatment trials based solely on number of prior medication failures, as recommended by the National Institute of Mental Health 2

The International Classification of Diseases is referenced as one method for diagnosing major depressive disorder, but treatment-resistant depression (TRD) itself lacks a dedicated code, and instead, the standard major depressive disorder ICD-10 codes (such as F32.x or F33.x) should be used, according to the American Psychiatric Association 7, 8, 9
Treatment resistance should be documented through clinical history rather than coding, as recommended by the American Psychiatric Association 7, 8

The Maudsley Staging Method (MSM) is a preferred documentation method for structured documentation, which incorporates the number of treatment failures, duration of illness, baseline symptom severity, augmentation strategies attempted, and ECT treatment history, with prospective validation and correctly predicts treatment resistance in >85% of cases, as stated by the National Institute of Mental Health 10, 11
Alternative documentation tools include the Antidepressant Treatment History Form (ATHF), which has good reliability and predictive validity for ECT studies, and careful clinical history documenting number, dose, duration, and adherence of prior trials, as recommended by the American Psychiatric Association 7, 8, 9, 12, 11

The American Academy of Family Physicians notes that fluoxetine should be at therapeutic dose (typically 20-40 mg daily) for at least 4 weeks before declaring inadequate response and adding aripiprazole 13
The American Family Physician guideline suggests considering drug interactions, such as fluoxetine's long half-life and cytochrome P450 enzyme inhibition, which can prolong effects and side effects for weeks 13